Cargando…

Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study

BACKGROUND: As the average age of the HIV-positive population increases, there is increasing need to monitor patients for the development of comorbidities as well as for drug toxicities. METHODS: We examined factors associated with the frequency of measurement of liver enzymes, renal function tests,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillis, Jennifer, Bayoumi, Ahmed M, Burchell, Ann N, Cooper, Curtis, Klein, Marina B, Loutfy, Mona, Machouf, Nima, Montaner, Julio SG, Tsoukas, Chris, Hogg, Robert S, Raboud, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620739/
https://www.ncbi.nlm.nih.gov/pubmed/26496954
http://dx.doi.org/10.1186/s12879-015-1206-3
_version_ 1782397344076005376
author Gillis, Jennifer
Bayoumi, Ahmed M
Burchell, Ann N
Cooper, Curtis
Klein, Marina B
Loutfy, Mona
Machouf, Nima
Montaner, Julio SG
Tsoukas, Chris
Hogg, Robert S
Raboud, Janet
author_facet Gillis, Jennifer
Bayoumi, Ahmed M
Burchell, Ann N
Cooper, Curtis
Klein, Marina B
Loutfy, Mona
Machouf, Nima
Montaner, Julio SG
Tsoukas, Chris
Hogg, Robert S
Raboud, Janet
author_sort Gillis, Jennifer
collection PubMed
description BACKGROUND: As the average age of the HIV-positive population increases, there is increasing need to monitor patients for the development of comorbidities as well as for drug toxicities. METHODS: We examined factors associated with the frequency of measurement of liver enzymes, renal function tests, and lipid levels among participants of the Canadian Observational Cohort (CANOC) collaboration which follows people who initiated HIV antiretroviral therapy in 2000 or later. We used zero-inflated negative binomial regression models to examine the associations of demographic and clinical characteristics with the rates of measurement during follow-up. Generalized estimating equations with a logit link were used to examine factors associated with gaps of 12 months or more between measurements. RESULTS: Electronic laboratory data were available for 3940 of 7718 CANOC participants. The median duration of electronic follow-up was 3.5 years. The median (interquartile) rates of tests per year were 2.76 (1.60, 3.73), 2.55 (1.44, 3.38) and 1.42 (0.50, 2.52) for liver, renal and lipid parameters, respectively. In multivariable zero-inflated negative binomial regression models, individuals infected through injection drug use (IDU) were significantly less likely to have any measurements. Among participants with at least one measurement, rates of measurement of liver, renal and lipid tests were significantly lower for younger individuals and Aboriginal Peoples. Hepatitis C co-infected individuals with a history of IDU had lower rates of measurement and were at greater risk of having 12 month gaps between measurements. CONCLUSIONS: Hepatitis C co-infected participants infected through IDU were at increased risk of gaps in testing, despite publicly funded health care and increased risk of comorbid conditions. This should be taken into consideration in analyses examining factors associated with outcomes based on laboratory parameters.
format Online
Article
Text
id pubmed-4620739
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46207392015-10-27 Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study Gillis, Jennifer Bayoumi, Ahmed M Burchell, Ann N Cooper, Curtis Klein, Marina B Loutfy, Mona Machouf, Nima Montaner, Julio SG Tsoukas, Chris Hogg, Robert S Raboud, Janet BMC Infect Dis Research Article BACKGROUND: As the average age of the HIV-positive population increases, there is increasing need to monitor patients for the development of comorbidities as well as for drug toxicities. METHODS: We examined factors associated with the frequency of measurement of liver enzymes, renal function tests, and lipid levels among participants of the Canadian Observational Cohort (CANOC) collaboration which follows people who initiated HIV antiretroviral therapy in 2000 or later. We used zero-inflated negative binomial regression models to examine the associations of demographic and clinical characteristics with the rates of measurement during follow-up. Generalized estimating equations with a logit link were used to examine factors associated with gaps of 12 months or more between measurements. RESULTS: Electronic laboratory data were available for 3940 of 7718 CANOC participants. The median duration of electronic follow-up was 3.5 years. The median (interquartile) rates of tests per year were 2.76 (1.60, 3.73), 2.55 (1.44, 3.38) and 1.42 (0.50, 2.52) for liver, renal and lipid parameters, respectively. In multivariable zero-inflated negative binomial regression models, individuals infected through injection drug use (IDU) were significantly less likely to have any measurements. Among participants with at least one measurement, rates of measurement of liver, renal and lipid tests were significantly lower for younger individuals and Aboriginal Peoples. Hepatitis C co-infected individuals with a history of IDU had lower rates of measurement and were at greater risk of having 12 month gaps between measurements. CONCLUSIONS: Hepatitis C co-infected participants infected through IDU were at increased risk of gaps in testing, despite publicly funded health care and increased risk of comorbid conditions. This should be taken into consideration in analyses examining factors associated with outcomes based on laboratory parameters. BioMed Central 2015-10-26 /pmc/articles/PMC4620739/ /pubmed/26496954 http://dx.doi.org/10.1186/s12879-015-1206-3 Text en © Gillis et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gillis, Jennifer
Bayoumi, Ahmed M
Burchell, Ann N
Cooper, Curtis
Klein, Marina B
Loutfy, Mona
Machouf, Nima
Montaner, Julio SG
Tsoukas, Chris
Hogg, Robert S
Raboud, Janet
Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
title Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
title_full Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
title_fullStr Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
title_full_unstemmed Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
title_short Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
title_sort factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620739/
https://www.ncbi.nlm.nih.gov/pubmed/26496954
http://dx.doi.org/10.1186/s12879-015-1206-3
work_keys_str_mv AT gillisjennifer factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT bayoumiahmedm factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT burchellannn factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT coopercurtis factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT kleinmarinab factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT loutfymona factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT machoufnima factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT montanerjuliosg factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT tsoukaschris factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT hoggroberts factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT raboudjanet factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy
AT factorsassociatedwiththefrequencyofmonitoringofliverenzymesrenalfunctionandlipidlaboratorymarkersamongindividualsinitiatingcombinationantiretroviraltherapyacohortstudy